New Document
Corporate Profile Products Investor Relations News Room Careers Contact Us Manufacturing Quality Assurance Environment, Health & Safety R & D Contract Research & Manufacturing Home
 

Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)

Financial Year 2005 - 2006

Quarter IV
(March 2006)

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003


QuarterIV
(March 2004)

Quarter III

(December 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)


AUDITED FINANCIAL RESULTS
FOR
THE QUARTER ENDED 30TH SEPTEMBER 2002


(Rs.in Million )
Sl. No Particulars Quarter ended 30.09.2002 (Audited) Quarter ended 30.09.2001
(UnAudited)
HalfYear ended 30.09.2002 (Audited) HalfYear ended 30.09.2001
(UnAudited)
Year ended 31.03.2002 (Audited)
  Gross Sales 603.19 197.26 1110.06 543.75 1038.89
01.
02.
03.






04.
05.
06.

07.
08.

09.
10.

11.

12.
13.

14.

15.

Net Sales
Other Income
Total Expenditure
a) (Increase)/Decrease in
Stock
b) Consumption of Raw
materials
c) Staff Cost
d) Other Expenditure
Interest
Depreciation
Profit before Tax & Extra-
ordinary items (1+2-3-4-5)
Provision for Tax
Net Profit after Tax and before
Extraordinary items(6-7)
Provision for Deferred Tax
Income Tax (inclusive of Deffered
Tax) for earlier years
Net Profit after Tax & Extraordinary items (8-9-10)
Paid up Equity Share Capital
Reserves excluding revaluation
reserves
Basic & Diluted E.P.S in Rs.
** (Not Annualised )
Aggregate of Non promoters Shareholding
Number of shares
Percentage of Shareholding
577.77
--
308.39

(19.69)

211.76
14.64
101.67
11.51
7.33

250.52
9.50

241.02
--

--

241.02
71.93

--
33.50



4430164
62
172.01
1.78
157.25

(17.60)

131.28
10.18
33.38
2.73
2.78

11.03
1.00

10.03
--

--

10.03
71.93

--
--



--
--
1067.31
0.76
575.57

5.22

355.79
27.82
186.73
20.07
12.31

460.10
12.50

447.60
3.63

--

443.96
71.93

--
61.72



--
--
483.85
1.78
442.83

(27.95)

352.91
20.06
97.82
6.21
5.22

31.37
1.00

30.37
--

--

30.37
71.93

135.96
5.14



--
--
932.07
1.78
826.35

(74.37)

670.52
49.45
180.75
16.73
15.25

75.51
4.60

70.91
15.70

10.38

44.82
71.93

143.25
10.83



--
--
Notes :

1. The above Audited Financial Results were reviewed in the Audit
    Committee and taken on record by the Board of Directors at
    their meeting held on 06.11.2002.

2. Income tax is computed for the Half year on the basis of annualized
    taxable income for the Asst. year 2003-04 after considering
    various deductions. Provision for Deffered Tax is computed for the
    Half Year ended 30.09.2002.

3. Accounting Standard No.17 dealing with Segment Accounting is not
    applicable as the company is engaged only in the segment of manufacture
    and sale of bulk drugs only.

4. The Board of Directors at their meeting held on 19.09.2002 have
    approved merger of Vorin Laboratories Ltd and Medicorp Technologies
    India Ltd into the Company, subject to requisite approvals. The appointed
    date for the merger is 01.04.2002.

    As per proposed scheme of merger, 2 Equity shares of Rs.10/-each fully
    paid of the Company shall be issued to the shareholders of Vorin Laboratories
    Limited and Medicorp Technologies India Ltd for every 13 Equity shares
    held by them in the respective companies.

5. The Company has completed aquisition of 33.89% out of the total Equity
    share capital of Rs.1924.45 lakhs in Medicorp Technologies India Ltd.
    The Company has also acquired 21% equity from Shriram Group,
    Chennai and transfer of Equity is under progress.

6. Pending requisite approval for the merger scheme, the financial
    results of Vorin Laboratories Ltd and Medicorp Technologies India
    Ltd have not been taken into account. Similarly impact on EPS has also
    not been considered.

7. The Board of Directors have recommended 50 % of interim dividend.

  For and on behalf of the Board



Place : Secunderabad
Date : 6th November 2002
Sd/-
N.PRASAD
Chairman & Managing Director


Foote Page